NEW YORK, July 10 - With $20 million from a private placement that closed Tuesday, ActivX Biosciences plans to double its scientific staff and build up its capabilities for applying its chemistry-based proteomics platform to drug discovery, chief operating officer Robert Hillman told GenomeWeb Tuesday.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.